Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells

Open access
Shibuya, Keita, Okada, Masashi, Suzuki, Shuhei, Seino, Manabu, Seino, Shizuka, Takeda, Hiroyuki, Kitanaka, Chifumi·2015·Oncotarget

Abstract

// Keita Shibuya 1,2,3,* , Masashi Okada 1,* , Shuhei Suzuki 1,4 , Manabu Seino 1,5 , Shizuka Seino 1,2,3,6 , Hiroyuki Takeda 1,4 and Chifumi Kitanaka 1,2,3,6 1 Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan 2 Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan 3 Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan 4 Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan 5 Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan 6 Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata, Japan * These authors contributed equally to this work Correspondence: Chifumi Kitanaka, email: // Keywords : cancer initiating cell, glioma, tumorigenicity, xenograft analysis Received : August 11, 2014 Accepted : November 25, 2014 Published : November 26, 2014 Abstract Increased glucose metabolism is now recognized as an emerging hallmark of cancer. Recent studies have shown that glucose metabolism is even more active in cancer stem cells (CSCs), a rare population of cancer cells with the capacity to self-renew and initiate tumors, and that CSCs are dependent on glycolysis for their survival/growth. However, the role of glucose metabolism in the control of their self-renewal and tumor-initiating capacity per se still remains obscure. Moreover, much remains unknown as to which of the numerous molecules involved in the glucose metabolism is suitable as a target to control CSCs. Here we demonstrate that the facilitative glucose transporter GLUT1 is essential for the maintenance of pancreatic, ovarian, and glioblastoma CSCs. Notably, we found that WZB117, a specific GLUT1 inhibitor, could inhibit the self-renewal and tumor-initiating capacity of the CSCs without compromising their proliferative potential in vitro . In vivo , systemic WZB117 administration inhibited tumor initiation after implantation of CSCs without causing significant adverse events in host animals. Our findings indicate GLUT1-dependent glucose metabolism has a pivotal role not only in the growth and survival of CSCs but also in the maintenance of their stemness and suggest GLUT1 as a promising target for CSC-directed cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2892

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 188

Metadata

Authors
Shibuya, K., Okada, M., Suzuki, S., Seino, M., Seino, S., Takeda, H., & Kitanaka, C.
Venue
Oncotarget
Published
2014-11-26
Volume
6
Issue
2
Pages
651-661
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1568188518
Cited by
188
References
2
FWCI
4.76
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.